<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Perspective Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/perspective-therapeutics-inc</link>
<description>Latest news and press releases for Perspective Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 10:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/perspective-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d73f9f51cc36e475330cb5.webp</url>
<title>Perspective Therapeutics, Inc.</title>
<link>https://6ix.com/company/perspective-therapeutics-inc</link>
</image>
<item>
<title>Perspective Therapeutics to Provide Several Upcoming Corporate Updates</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-provide-several-upcoming-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-provide-several-upcoming-corporate-updates</guid>
<pubDate>Fri, 24 Apr 2026 10:30:00 GMT</pubDate>
<description>SEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will provide several corporate updates in May 2026. Webcasts of these events, unless noted as press release only, will be posted on the Company's website at www.perspectivetherapeutics.com. Analyst Event on Perspective’s Strategy, Enabling</description>
</item>
<item>
<title>Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-presents-updated-interim-data-of-212pbvmt-a-net-in-its-ongoing-phase-12a-clinical-trial-at-the-2026-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-presents-updated-interim-data-of-212pbvmt-a-net-in-its-ongoing-phase-12a-clinical-trial-at-the-2026-aacr-annual-meeting</guid>
<pubDate>Mon, 20 Apr 2026 10:00:00 GMT</pubDate>
<description>Updated interim results with an additional ~12 weeks of follow-up since prior update at ASCO-GI in January 2026 and ~25 weeks since ESMO in October 2025Safety update presented on all 64 patients who received at least one treatment and updated efficacy analysis presented on the two patients in Cohort 1 and 23 patients in Cohort 2Objective response in 43% (10 out of 23) of patients in first half of Cohort 2, including an additional new response and confirmation of the initial response reported at</description>
</item>
<item>
<title>Perspective Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-participate-in-upcoming-investor-conferences-5</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-participate-in-upcoming-investor-conferences-5</guid>
<pubDate>Thu, 02 Apr 2026 11:00:00 GMT</pubDate>
<description>SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: 25th Annual Needham Virtual Healthcare Conference – Presentation & Fireside ChatDate: Tue</description>
</item>
<item>
<title>Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-announces-acceptance-of-vmt-a-net-data-for-presentation-at-the-aacr-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-announces-acceptance-of-vmt-a-net-data-for-presentation-at-the-aacr-annual-meeting-2026</guid>
<pubDate>Tue, 17 Mar 2026 20:45:00 GMT</pubDate>
<description>SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted as a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place from April 17 to 22, 2026 in San Diego, CA as detailed</description>
</item>
<item>
<title>Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-provides-recent-business-highlights-and-reports-full-year-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-provides-recent-business-highlights-and-reports-full-year-2025-results</guid>
<pubDate>Mon, 16 Mar 2026 20:07:00 GMT</pubDate>
<description>Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026VMT-α-NET study on track to achieve nearly one year of follow-up in all 46 patients in Cohort 2 by mid-2026; analysis to inform patient selection strategy ongoingData across all dose levels in the VMT-α-NET program provide development optionality and support the build-out of a robus</description>
</item>
<item>
<title>Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-provide-business-highlights-and-report-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-provide-business-highlights-and-report-full-year-2025-financial-results</guid>
<pubDate>Tue, 17 Feb 2026 12:00:00 GMT</pubDate>
<description>SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its full year 2025 financial results and provide a business update on Monday, March 16, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivethe</description>
</item>
<item>
<title>Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-announces-pricing-of-dollar175-million-underwritten-offering-of-common-stock-and-pre-funded-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-announces-pricing-of-dollar175-million-underwritten-offering-of-common-stock-and-pre-funded-warrants</guid>
<pubDate>Mon, 02 Feb 2026 13:35:00 GMT</pubDate>
<description>SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced the pricing of an underwritten offering of 39,576,088 shares of its common stock at an offering price of $3.79 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 6,598,046 shares of its common stock at a price</description>
</item>
<item>
<title>Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-provides-business-updates-and-strategic-priorities-ahead-of-presentation-at-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-provides-business-updates-and-strategic-priorities-ahead-of-presentation-at-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data package for presentation to more medical conferences in 2026, as well as regulatory engagementVMT-α-NET continues to be well-tolerated and shows durable disease control and deepening of tumor response with longer follow-up as reported at ASCO-GI 2026 Clinical updates expected in mid to late 2026 for VMT01 targeting melanoma and PSV359 targeting FAP acros</description>
</item>
<item>
<title>Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-presents-updated-interim-data-of-212pbvmt-a-net-in-its-ongoing-phase-12a-clinical-trial-at-the-2026-asco-gastrointestinal-cancers-symposium</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-presents-updated-interim-data-of-212pbvmt-a-net-in-its-ongoing-phase-12a-clinical-trial-at-the-2026-asco-gastrointestinal-cancers-symposium</guid>
<pubDate>Fri, 09 Jan 2026 12:00:00 GMT</pubDate>
<description>Updated interim results with an additional ~13 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-tolerated Updated efficacy analysis suggests durable disease control and deepening of tumor response per RECIST v1.1 in the first 23 patients in Cohort 2 and both patients in Cohort 1Objective response in 39% of patients in Cohort 2 regardless of SSTR2 expression profile, including one Cohort 2 patient who experienced an initial objective response pending confirmation sin</description>
</item>
<item>
<title>Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-present-at-the-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-present-at-the-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Thu, 18 Dec 2025 12:00:00 GMT</pubDate>
<description>SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14, 2026, at 2:15 p.m. PT. 44th Annual J.P. Morgan Healthcare Conference – Company Presentation</description>
</item>
<item>
<title>Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-announces-acceptance-of-vmt-a-net-data-for-presentation-at-the-asco-gastrointestinal-cancers-symposium</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-announces-acceptance-of-vmt-a-net-data-for-presentation-at-the-asco-gastrointestinal-cancers-symposium</guid>
<pubDate>Thu, 04 Dec 2025 12:00:00 GMT</pubDate>
<description>SEATTLE, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) Congress 2026 taking place from January 8 to 10, 2026 in San F</description>
</item>
<item>
<title>Perspective Therapeutics to Participate in Upcoming December Conferences</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-participate-in-upcoming-december-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-participate-in-upcoming-december-conferences</guid>
<pubDate>Thu, 20 Nov 2025 12:00:00 GMT</pubDate>
<description>SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: Piper Sandler & Co. 37th Annual Healthcare Conference – Fireside ChatD</description>
</item>
<item>
<title>Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-provides-recent-business-highlights-and-reports-3q-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-provides-recent-business-highlights-and-reports-3q-2025-results</guid>
<pubDate>Mon, 10 Nov 2025 21:05:00 GMT</pubDate>
<description>Updated interim results from the Company’s [212Pb]VMT-α-NET Phase 1/2a study supporting the therapy’s compelling overall clinical profile at the 5 mCi dose were presented at the ESMO Congress 2025, NANETS and Triple meetingsEnrolled eight patients into Cohort 3 (6.0 mCi) of the [212Pb]VMT-α-NET study within three months of opening the cohortVisibility on updates for all three of the Company’s clinical-stage potential new medicines expected throughout 2026 based on strong recruitment of patients</description>
</item>
<item>
<title>Perspective Therapeutics to Participate in Upcoming November Conferences</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-participate-in-upcoming-november-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-participate-in-upcoming-november-conferences</guid>
<pubDate>Fri, 31 Oct 2025 11:00:00 GMT</pubDate>
<description>SEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: Truist Securities BioPharma Symposium – 1x1 onlyDate: Thursday, November 6, 2025Location:</description>
</item>
<item>
<title>Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-provide-business-highlights-and-report-third-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-provide-business-highlights-and-report-third-quarter-2025-financial-results</guid>
<pubDate>Fri, 24 Oct 2025 11:00:00 GMT</pubDate>
<description>SEATTLE, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its third quarter 2025 financial results and provide a business update on Monday, November 10, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspec</description>
</item>
<item>
<title>Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-announces-first-patient-dosed-with-psv359-in-the-second-cohort-of-a-phase-12a-study-in-patients-with-fap-a-positive-solid-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-announces-first-patient-dosed-with-psv359-in-the-second-cohort-of-a-phase-12a-study-in-patients-with-fap-a-positive-solid-tumors</guid>
<pubDate>Thu, 02 Oct 2025 11:00:00 GMT</pubDate>
<description>SEATTLE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced that the first patient was treated with [212Pb]PSV359 in a second cohort of the Company’s Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that</description>
</item>
<item>
<title>Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-progresses-dose-finding-for-212pbvmt01-in-combination-with-nivolumab-in-its-ongoing-phase-12a-study-of-mc1r-positive-metastatic-melanoma</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-progresses-dose-finding-for-212pbvmt01-in-combination-with-nivolumab-in-its-ongoing-phase-12a-study-of-mc1r-positive-metastatic-melanoma</guid>
<pubDate>Mon, 15 Sep 2025 11:00:00 GMT</pubDate>
<description>First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted</description>
</item>
<item>
<title>Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-appoints-biotech-veteran-joel-sendek-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-appoints-biotech-veteran-joel-sendek-as-chief-financial-officer</guid>
<pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
<description>Distinguished career as a Wall Street analyst and significant CFO experience, bringing keen insights and understanding of finance and the life sciences investment landscapeSEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company’s Chief Financial Officer, effective toda</description>
</item>
<item>
<title>Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-appoints-maya-martinez-davis-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-appoints-maya-martinez-davis-to-board-of-directors</guid>
<pubDate>Wed, 03 Sep 2025 11:00:00 GMT</pubDate>
<description>SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company’s Board of Directors, effective today. Ms. Martinez-Davis currently serves as President of GSK’s U.S. Commercial business, a position she has held since Se</description>
</item>
<item>
<title>Perspective Therapeutics to Participate in Upcoming September Conferences</title>
<link>https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-participate-in-upcoming-september-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/perspective-therapeutics-inc/news/perspective-therapeutics-to-participate-in-upcoming-september-conferences</guid>
<pubDate>Tue, 26 Aug 2025 11:00:00 GMT</pubDate>
<description>SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences. Cantor Global Healthcare Conference – Fireside ChatDate: Thursday, September 4, 2025Time: 1:00 p.m. -</description>
</item>
</channel>
</rss>